Verzenio + Aromatase Inhibitor
Explore the effectiveness, dosing, and common side effects of Verzenio + an Aromatase Inhibitor.
How effective is Verzenio + aromatase inhibitor (AI)?
Verzenio was studied in combination with an AI as initial endocrine-based therapy in 493 postmenopausal women with newly diagnosed hormone receptor‑positive (HR+), human epidermal growth factor receptor 2‑negative (HER2–) advanced or metastatic breast cancer (MBC). 328 patients were treated with Verzenio + AI and 165 were treated with an AI alone.
Clinical trials are still ongoing to determine if there is an overall survival benefit with Verzenio.
Live longer without cancer getting worse
Verzenio + an AI delayed disease progression for over 2 years (a median of 28.2 months) vs 14.8 months with an AI alone
More than half of the women saw their tumors shrink
55.4% of women on Verzenio + an AI saw their tumors shrink vs 40.2% on an AI alone
Complete response: no detectable signs of cancer
3.4% of women on Verzenio + an AI had a complete response, or no detectable sign of cancer, vs 0% with an AI alone
Partial response: tumor shrinkage of 30% or more
52.1% of women on Verzenio + an AI had a partial response with tumor shrinkage of 30% or more vs 40.2% with an AI alone
SELECT SAFETY INFORMATION
Verzenio may cause serious side effects, including:
Diarrhea is common with Verzenio, may be severe and may cause dehydration or infection. The most common time to develop diarrhea is during the first month of Verzenio treatment. Your doctor may stop your treatment, lower your dose, or tell you to wait to begin your treatment cycle if you have diarrhea.
At the first sign of loose stools, tell your doctor. You may be advised to start taking an antidiarrheal medicine (such as loperamide) and drink more fluids.